| scholarly article | Q13442814 |
| P50 | author | Patrick Craig Walsh | Q2057508 |
| Edward M Schaeffer | Q62069731 | ||
| Jonathan I. Epstein | Q88404078 | ||
| P2093 | author name string | Stacy Loeb | |
| Bruce J Trock | |||
| Elizabeth B Humphreys | |||
| P2860 | cites work | Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial | Q24605205 |
| 6-month androgen suppression plus radiation therapy vs radiation therapy alone for patients with clinically localized prostate cancer: a randomized controlled trial | Q34341758 | ||
| Guideline for the management of clinically localized prostate cancer: 2007 update. | Q34629234 | ||
| Preventing and treating the complications of hormone therapy | Q36115635 | ||
| Surgeon experience is strongly associated with biochemical recurrence after radical prostatectomy for all preoperative risk categories | Q36597008 | ||
| Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy | Q36909962 | ||
| Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. | Q36945391 | ||
| Secondary therapy, metastatic progression, and cancer-specific mortality in men with clinically high-risk prostate cancer treated with radical prostatectomy | Q37086821 | ||
| Clinical and pathologic outcome after radical prostatectomy for prostate cancer patients with a preoperative Gleason sum of 8 to 10. | Q42594983 | ||
| Changing nature of high risk patients undergoing radical prostatectomy | Q44006823 | ||
| The specific definition of high risk prostate cancer has minimal impact on biochemical relapse-free survival | Q44570551 | ||
| Treatment of patients with high risk localized prostate cancer: results from cancer of the prostate strategic urological research endeavor (CaPSURE). | Q46269625 | ||
| Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. | Q47824845 | ||
| Biochemical outcome after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. | Q55067996 | ||
| Influence of Androgen Suppression Therapy for Prostate Cancer on the Frequency and Timing of Fatal Myocardial Infarctions | Q58229260 | ||
| Trends and predictors of aggressive therapy for clinical locally advanced prostate carcinoma | Q59193478 | ||
| Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin | Q59364974 | ||
| Intermediate-Term Potency, Continence, and Survival Outcomes of Radical Prostatectomy for Clinically High-Risk or Locally Advanced Prostate Cancer | Q59563499 | ||
| Radical prostatectomy for clinical stage T3a disease | Q79812032 | ||
| Radical prostatectomy for clinically localized, high risk prostate cancer: critical analysis of risk assessment methods | Q80461562 | ||
| Mayo Clinic validation of the D'amico risk group classification for predicting survival following radical prostatectomy | Q80744531 | ||
| Anatomical extent of lymph node dissection: impact on men with clinically localized prostate cancer | Q80995021 | ||
| P433 | issue | 3 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | prostate cancer | Q181257 |
| P304 | page(s) | 710-714 | |
| P577 | publication date | 2009-11-22 | |
| P1433 | published in | Urology | Q7900884 |
| P1476 | title | What are the outcomes of radical prostatectomy for high-risk prostate cancer? | |
| P478 | volume | 76 |
| Q36584742 | A Novel Quantitative Multiplex Tissue Immunoblotting for Biomarkers Predicts a Prostate Cancer Aggressive Phenotype. |
| Q55490854 | Age-adjusted Charlson Comorbidity Index as a prognostic factor for radical prostatectomy outcomes of very high-risk prostate cancer patients. |
| Q37421914 | An updated prostate cancer staging nomogram (Partin tables) based on cases from 2006 to 2011. |
| Q41630001 | Assessing the clinical benefit of a nomogram to predict specimen-confined disease at radical prostatectomy in patients with high-risk prostate cancer: An external validation |
| Q36042621 | Biochemical recurrence-free survival and pathological outcomes after radical prostatectomy for high-risk prostate cancer |
| Q38151298 | Can we improve the definition of high-risk, hormone naïve, non-metastatic prostate cancer? |
| Q47100168 | Cancer-specific mortality of high-risk prostate cancer after carbon-ion radiotherapy plus long-term androgen deprivation therapy. |
| Q37692803 | Clinical implications of changing definitions within the Gleason grading system |
| Q37689256 | Contemporaneous comparison of open vs minimally-invasive radical prostatectomy for high-risk prostate cancer |
| Q34346841 | Current status of radical prostatectomy for high-risk prostate cancer. |
| Q52905066 | Efficacy of a neoadjuvant gonadotropin-releasing hormone antagonist plus low-dose estramustine phosphate in high-risk prostate cancer: a single-center study. |
| Q33676155 | End-of-radiation PSA as a novel prognostic factor in patients undergoing definitive radiation and androgen deprivation therapy for prostate cancer |
| Q41856230 | Ensuring quality for radical prostatectomies in Canada. |
| Q95728090 | Gleason Pattern 5 is a Possible Pathologic Predictor for Biochemical Recurrence after Laparoscopic Radical Prostatectomy |
| Q37861198 | High-risk prostate cancer: the role of radical prostatectomy for local therapy |
| Q45938587 | How does robot-assisted radical prostatectomy (RARP) compare with open surgery in men with high-risk prostate cancer? |
| Q88197455 | Identification of curable high-risk prostate cancer using radical prostatectomy alone: who are the good candidates for undergoing radical prostatectomy among patients with high-risk prostate cancer? |
| Q33825388 | Identification of men with the highest risk of early disease recurrence after radical prostatectomy |
| Q37509084 | Impact of stage migration and practice changes on high-risk prostate cancer: results from patients treated with radical prostatectomy over the last two decades |
| Q91939868 | Management of advanced prostate cancer in a middle-income country: real-world consideration of the Advanced Prostate Cancer Consensus Conference 2017 |
| Q46066104 | Matching tumor risk with aggressiveness of treatment in men with multiple comorbidities and early-stage prostate cancer |
| Q34111597 | Multimodal Approaches to High-Risk Prostate Cancer |
| Q41436143 | Neoadjuvant luteinizing-hormone-releasing hormone agonist plus low-dose estramustine phosphate improves prostate-specific antigen-free survival in high-risk prostate cancer patients: a propensity score-matched analysis |
| Q38598269 | New surgical approaches for clinically high-risk or metastatic prostate cancer |
| Q40897976 | Older patients with low Charlson score and high-risk prostate cancer benefit from radical prostatectomy. |
| Q37014814 | Oncologic Outcome of Radical Prostatectomy as Monotherapy for Men with High-risk Prostate Cancer |
| Q36492451 | Optimizing the management of high-risk, localized prostate cancer |
| Q41955736 | Outcomes of Gleason Score ≤ 8 among high risk prostate cancer treated with 125I low dose rate brachytherapy based multimodal therapy |
| Q93036248 | Outcomes of very high-risk prostate cancer after radical prostatectomy: Validation study from 3 centers |
| Q47329081 | Overall survival of high-risk prostate cancer patients who received neoadjuvant chemohormonal therapy followed by radical prostatectomy at a single institution |
| Q42353499 | Partial prostatectomy: technically feasible, but patient selection is paramount |
| Q58593662 | Pathological outcomes and biochemical recurrence-free survival after radical prostatectomy for high-risk prostate cancer in the Indian population |
| Q43425184 | Percentage of high-grade tumour volume does not meaningfully improve prediction of early biochemical recurrence after radical prostatectomy compared with Gleason score |
| Q40084992 | Population-based 10-year event-free survival after radical prostatectomy for patients with prostate cancer in British Columbia |
| Q51009611 | Predicting pathological outcomes in patients undergoing robot-assisted radical prostatectomy for high-risk prostate cancer: a preoperative nomogram. |
| Q34013761 | Preoperative characteristics of high-Gleason disease predictive of favourable pathological and clinical outcomes at radical prostatectomy |
| Q50769648 | Preoperative predictive factors and further risk stratification of biochemical recurrence in clinically localized high-risk prostate cancer. |
| Q53129243 | Prognostic significance of primary Gleason pattern in Japanese men with Gleason score 7 prostate cancer treated with radical prostatectomy. |
| Q62524728 | Prostate biopsy perineural invasion is not independently associated with positive surgical margins following radical retropubic prostatectomy |
| Q43523307 | Prostate-specific antigen density predicts extracapsular extension and increased risk of biochemical recurrence in patients with high-risk prostate cancer who underwent radical prostatectomy |
| Q64255908 | Radical Prostatectomy and Pelvic Lymph Node Dissection in Kaiser Permanente Southern California: 15-Year Experience |
| Q37982319 | Radical prostatectomy as primary treatment of high-risk prostate cancer |
| Q35605772 | Radical prostatectomy for high-risk clinically localized prostate cancer: a prospective single institution series. |
| Q46495723 | Radical prostatectomy for high-risk prostate cancer defined by preoperative criteria: oncologic follow-up in national multicenter study in 813 patients and assessment of easy-to-use prognostic substratification |
| Q92436120 | Radical prostatectomy for high-risk prostate cancer | Opinion: NO |
| Q43437975 | Radical prostatectomy in clinically localized high-risk prostate cancer: outcome of 231 consecutive patients. |
| Q38280317 | Radical prostatectomy in high-risk and locally advanced prostate cancer: Mayo Clinic perspective |
| Q57131976 | Radical prostatectomy in high-risk prostate cancer |
| Q51521214 | Robotic radical prostatectomy as the initial step in multimodal therapy for men with high-risk localised prostate cancer: initial experience of 160 men. |
| Q34139187 | Role of radical prostatectomy for high-risk prostate cancer |
| Q38101613 | Salvage treatment in prostate cancer: a clinical approach |
| Q36236135 | Secreted protein, acidic and rich in cysteine-like 1 (SPARCL1) is down regulated in aggressive prostate cancers and is prognostic for poor clinical outcome |
| Q35704002 | Short-term clinicopathological outcome of neoadjuvant chemohormonal therapy comprising complete androgen blockade, followed by treatment with docetaxel and estramustine phosphate before radical prostatectomy in Japanese patients with high-risk local |
| Q53638673 | Significance of apoptotic and non-apoptotic disseminated tumor cells in the bone marrow of patients with clinically localized prostate cancer. |
| Q40420529 | Significant increase in prostatectomy and decrease in radiation for clinical T3 prostate cancer from 1998 to 2012. |
| Q36202488 | The Association of Fatty Acid Levels and Gleason Grade among Men Undergoing Radical Prostatectomy |
| Q57885583 | The impact of pathologic staging on the long-term oncologic outcomes of patients with clinically high-risk prostate cancer |
| Q38501645 | The long-term outcomes after radical prostatectomy of patients with pathologic Gleason 8-10 disease. |
| Q26849794 | The role of magnetic resonance imaging in the diagnosis and management of prostate cancer |
| Q37270502 | The role of radical prostatectomy in high-risk prostate cancer |
| Q37939464 | The role of surgery in high-risk localised prostate cancer |
| Q38211115 | The status of surgery in the management of high-risk prostate cancer |
| Q38068495 | Triptorelin in the management of prostate cancer |
| Q37342181 | Very High-Risk Localized Prostate Cancer: Outcomes Following Definitive Radiation. |
| Q41020184 | Very long-term survival patterns of young patients treated with radical prostatectomy for high-risk prostate cancer |
| Q37623723 | Very-high-risk localized prostate cancer: definition and outcomes |
| Q84484662 | What is the best way to treat high-risk prostate cancer? |
Search more.